Clearside Biomedical (NSDQ:CLSD) said today that it landed a deal with EyeKor Inc. to support its clinical trials. The companies did not disclose any financial details of the agreement.
Clearside is conducting a Phase III trial of suprachoroidally administered CLS-TA, its suspension formulation of triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis. The company is also evaluating its suprachoroidal CLS-TA, in combination with intravitreally administered Eyelea (aflibercept), in patients with macular edema associated with retinal vein occlusion.
Get the full story at our sister site, Drug Delivery Business News.